Venn Life Sciences

Pharma services business Open Orphan, formerly known as Venn Life Sciences, has resumed trading on the stock exchanges in Dublin and London following (...)

Dublin-listed drug clinical trials manager Venn Life Sciences, which is in the process of merging with dealmaker Cathal Friel’s pharma services busine(...)

Leading corporate figure Cathal Friel is behind the proposed reverse takeover of listed clinical trials group Venn Life Sciences by pharma services bu(...)

A Canadian speciality pharmaceutical company has appointed Dublin man Conor Walshe as general manager of its European subsidiary. Theratechnologies,(...)

Clinical trials group Venn Life Sciences has signed a strategic collaboration with Open Orphan DAC as it seeks to increase its focus on rare diseases (...)

Big Pharma in Ireland has an image problem. At least that’s how it sees it. “I think we are not seen as a trusted partner,” says Aidan Lynch, presid(...)

Shares in clinical trials group Venn Life Sciences fell to a new low after it reported a fall in sales and wider losses for the first six months of th(...)

Having assumed the role of chief executive of Venn Life Sciences in 2010, Tony Richardson quickly set about expanding the company, completing two acqu(...)

Drug development firm Venn Life Sciences has raised £650,000 before expenses in a share sale. The company, which provides clinical trials services to(...)

Drug development firm Venn Life Sciences said it reported an overall loss of €1.5 million for last year as charges related to its investment in Dalkey(...)